NEW YORK, Aug. 26, 2004 (PRIMEZONE) -- Advanced Plant Pharmaceuticals, Inc. ("APPI") (OTCBB:APPI) announced today that it has appointed Dr. Mechael Kanovsky to spearhead the Company's recently commenced pharmaceutical drug development program. This program has been initiated by APPI in order to develop three proposed "whole plant" pharmaceutical drugs from the Company's R&D program for High Cholesterol, Leukemia and Alzheimer's.
Dr. Kanovsky will play an important role in our attempt to obtain FDA approval for the three proposed "whole plant" pharmaceutical drugs.
"We are quite pleased with this appointment of Dr. Kanovsky," stated David Lieberman, CEO of APPI. "His extensive knowledge of pathology, as well as his work on innovative therapies to treat cancer and other disease, will be extremely beneficial to our pharmaceutical drug development program."
Dr. Mechael Kanovsky has been involved in cancer research for many years. Dr. Kanovsky performs most of his research in the Department of Pathology and Laboratory Medicine at the VA Medical Center, and in the SUNY health Science Center, both located in Brooklyn, New York. He has a Ph.D. in molecular biology from Mount Sinai Medical School, New York.
About Advanced Plant Pharmaceuticals:
Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of whole plant-based nutritionals. The company has a composition-oriented patent for a proprietary process of utilizing whole plants to safely manufacture all-natural nutritional supplements. APPI markets and distributes its line of products including Lo-Chol(tm) worldwide through various sales distribution channels. For more information, visit the Company's Corporate website: www.advancedplantpharm.com
Forward-Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.